ReviewThe European respiratory journal2024
Clinical trial design, end-points, and emerging therapies in pulmonary arterial hypertension.
Review in The European respiratory journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Chest · 2025Trial
- Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Chest · 2025Trial
- Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.Chest · 2025Trial
- Activin Signaling Inhibitors in Pulmonary Hypertension: A State-of-the-Art Review.Pulmonary circulation · 2026Review
- 2025 Annual Review of Pulmonary Arterial Hypertension Clinical Research.Pulmonary therapy · 2026Review
- One Health Insights into Pulmonary Hypertension: Bridging Human and Canine Medicine.Veterinary sciences · 2026Review
- Multifaceted mechanisms of plant metabolites in pulmonary arterial hypertension: a critical review beyond vasodilation.Frontiers in pharmacology · 2026Review
- The Pathophysiology, Mechanism, Diagnosis, and Management of Pulmonary Arterial Hypertension: A Comprehensive Literature Review.US cardiology · 2026Review
- Insights from the Pulmonary Hypertension Global Patient Survey: challenges in pulmonary hypertension care abound but so do opportunities.ERJ open research · 2025Article
- The Pulmonary Hypertension Global Patient Survey: understanding the experiences and perspectives of patients.ERJ open research · 2025Article
- Cluster analysis identifies quantitative CT imaging-based subgroups in COPD subjects with pulmonary artery enlargement.The European respiratory journal · 2025Article
- Article
- Pulmonary hypertension aetiologies in different parts of the world.International journal of cardiology. Congenital heart disease · 2025Review
- Another Act in the Story of Oral Imatinib for Pulmonary Arterial Hypertension.American journal of respiratory and critical care medicine · 2025Article
- PVRI International Conference 2025: Embracing Heterogeneity.Pulmonary circulation · 2025Article
- Emerging Mechanistic Insights and Therapeutic Strategies for Pulmonary Arterial Hypertension: A Focus on Right Ventricular Dysfunction and Novel Treatment Pathways.Biomedicines · 2025Review
- Chest Computed Tomography to Improve Phenotyping in Pulmonary Hypertension Associated with Chronic Obstructive Pulmonary Disease.Annals of the American Thoracic Society · 2025Article
Corrections and comments
- Commented on by
Authors and funding
9 authors.
Funding
Abstract
Clinical trials in pulmonary arterial hypertension (PAH) have led to the approval of several effective treatments that improve symptoms, exercise capacity and clinical outcomes. In phase 3 clinical trials, primary end-points must reflect how a patient "feels, functions or survives". In a rare disease like PAH, with an ever-growing number of treatment options and numerous candidate therapies being studied, future clinical trials are now faced with challenges related to sample size requirements, efficiency and demonstration of incremental benefit on traditional end-points in patients receiving background therapy with multiple drugs. Novel clinical trial end-points, innovative trial designs and statistical approaches and new technologies may be potential solutions to tackle the challenges facing future PAH trials, but these must be acceptable to patients and regulatory bodies while preserving methodological rigour. In this World Symposium on Pulmonary Hypertension task force article, we address emerging trial end-points and designs, biomarkers and surrogate end-point validation, the concept of disease modification, challenges and opportunities to address diversity and representativeness, and the use of new technologies such as artificial intelligence in PAH clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.